160 related articles for article (PubMed ID: 26325374)
21. Protein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-hodgkin lymphoma cells.
Saba NS; Levy LS
J Investig Med; 2012 Jan; 60(1):29-38. PubMed ID: 21997316
[TBL] [Abstract][Full Text] [Related]
22. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
23. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor.
Qing Y; Shuo W; Zhihua W; Huifen Z; Ping L; Lijiang L; Xiaorong Z; Liming C; Daiwen X; Yu H; Wei X; Min F; Zuohua F; Guanxin S
Cancer Immunol Immunother; 2006 Sep; 55(9):1111-21. PubMed ID: 16341531
[TBL] [Abstract][Full Text] [Related]
24. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells.
Daniels TR; Neacato II; Rodríguez JA; Pandha HS; Morgan R; Penichet ML
Leukemia; 2010 Sep; 24(9):1555-65. PubMed ID: 20574452
[TBL] [Abstract][Full Text] [Related]
25. Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer.
Nagai K; Nakahata S; Shimosaki S; Tamura T; Kondo Y; Baba T; Taki T; Taniwaki M; Kurosawa G; Sudo Y; Okada S; Sakoda S; Morishita K
Cancer Med; 2014 Aug; 3(4):1085-99. PubMed ID: 24890018
[TBL] [Abstract][Full Text] [Related]
26. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
27. Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors.
Arumov A; Liyanage PY; Trabolsi A; Roberts ER; Li L; Ferreira BCLB; Gao Z; Ban Y; Newsam AD; Taggart MW; Vega F; Bilbao D; Leblanc RM; Schatz JH
Cancer Res; 2021 Feb; 81(3):763-775. PubMed ID: 33177062
[TBL] [Abstract][Full Text] [Related]
28. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
29. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.
Pagel JM; Spurgeon SE; Byrd JC; Awan FT; Flinn IW; Lanasa MC; Eisenfeld AJ; Stromatt SC; Gopal AK
Br J Haematol; 2015 Jan; 168(1):38-45. PubMed ID: 25146490
[TBL] [Abstract][Full Text] [Related]
30. Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1.
Stocki P; Szary J; Rasmussen CLM; Demydchuk M; Northall L; Logan DB; Gauhar A; Thei L; Moos T; Walsh FS; Rutkowski JL
FASEB J; 2021 Feb; 35(2):e21172. PubMed ID: 33241587
[TBL] [Abstract][Full Text] [Related]
31. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain.
Penichet ML; Kang YS; Pardridge WM; Morrison SL; Shin SU
J Immunol; 1999 Oct; 163(8):4421-6. PubMed ID: 10510383
[TBL] [Abstract][Full Text] [Related]
32. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
33. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
34. The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses.
Runyon K; Lee K; Zuberek K; Collins M; Leonard JP; Dunussi-Joannopoulos K
Blood; 2001 Apr; 97(8):2420-6. PubMed ID: 11290606
[TBL] [Abstract][Full Text] [Related]
35. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
36. Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway.
Wang Y; Deng M; Chen Q; Li Y; Guo X; Shi P; He L; Xie S; Yu L; Zhang H; Xu B
Eur J Pharmacol; 2019 Jan; 843():145-153. PubMed ID: 30423319
[TBL] [Abstract][Full Text] [Related]
37. Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections.
Hickerson BT; Daniels-Wells TR; Payes C; Clark LE; Candelaria PV; Bailey KW; Sefing EJ; Zink S; Ziegenbein J; Abraham J; Helguera G; Penichet ML; Gowen BB
Nat Commun; 2022 Jan; 13(1):558. PubMed ID: 35091550
[TBL] [Abstract][Full Text] [Related]
38. Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.
Hariharan K; Chu P; Murphy T; Clanton D; Berquist L; Molina A; Ho SN; Vega MI; Bonavida B
Int J Oncol; 2013 Aug; 43(2):670-6. PubMed ID: 23764770
[TBL] [Abstract][Full Text] [Related]
39. Transferrin receptor 1: a target for antibody-mediated cancer therapy.
Daniels-Wells TR; Penichet ML
Immunotherapy; 2016 Sep; 8(9):991-4. PubMed ID: 27373880
[No Abstract] [Full Text] [Related]
40. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.
McEarchern JA; Oflazoglu E; Francisco L; McDonagh CF; Gordon KA; Stone I; Klussman K; Turcott E; van Rooijen N; Carter P; Grewal IS; Wahl AF; Law CL
Blood; 2007 Feb; 109(3):1185-92. PubMed ID: 17038522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
